Keywords: Bristol-Myers Squibb, Pfizer, Apixaban, Acute coronary syndrome, Axitinib, Renal cell carcinoma

Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib

Article | 22 November 2010

Print This

As a result of drug side effects seen in the Phase III APPRAISE-2 clinical trial in patients with recent acute ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in